NCT07132099 Randomized Suicide Prevention Trial Using ASSIP and ACT in Suicide Attempters
| NCT ID | NCT07132099 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ardakan University |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2025-09-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-08-01 with a primary completion date of 2025-09-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized controlled trial that aims to compare the effectiveness of two psychological treatment approaches: the Attempted Suicide Short Intervention Program (ASSIP) and Acceptance and Commitment Therapy (ACT). The study seeks to determine which of these two methods is more effective in reducing suicidal ideation and mental pain in individuals who have recently attempted suicide. In this study, 60 participants with a history of suicide attempts will be randomly assigned to three groups. One group will receive ASSIP in addition to treatment as usual (TAU), the second group will receive ACT alongside TAU, and the third group will be a control group receiving TAU only. The results will be assessed using the Beck Scale for Suicide Ideation (BSSI) and the Orbach \& Mikulincer Mental Pain Scale (OMMP) at three stages: pre-test, post-test, and follow-up. The ultimate goal of this research is to provide valuable insights into the comparative effectiveness of ASSIP and ACT interventions for suicide attempters and to contribute to evidence-based suicide prevention strategies. The findings are expected to inform clinical practice and guide future research in this field.
Eligibility Criteria
Inclusion Criteria: * Being 18 years of age or older * Having the ability to read and write * Providing informed consent to participate in the study * Having at least one suicide attempt in the past 4 months Exclusion Criteria: * Having a severe psychiatric or physical illness that interferes with the treatment process * Receiving concurrent structured psychological interventions (other than TAU) that may interfere with the study's treatment process. * Lack of informed consent to participate in the study * Substance abuse based on DSM-5 criteria
Contact & Investigator
Azadeh Choobforoushzadeh, PhD
STUDY DIRECTOR
Ardakan University
Frequently Asked Questions
Who can join the NCT07132099 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07132099 currently recruiting?
Yes, NCT07132099 is actively recruiting participants. Contact the research team at yaghoobih98@gmail.com for enrollment information.
Where is the NCT07132099 trial being conducted?
This trial is being conducted at Eslamshahr, Iran.
Who is sponsoring the NCT07132099 clinical trial?
NCT07132099 is sponsored by Ardakan University. The principal investigator is Azadeh Choobforoushzadeh, PhD at Ardakan University. The trial plans to enroll 60 participants.